BioHarvest Sciences (NASDAQ:BHST – Get Free Report) posted its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04), FiscalAI reports. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The company had revenue of $8.84 million during the quarter, compared to analyst estimates of $9.45 million.
BioHarvest Sciences Stock Performance
Shares of BHST stock traded up $0.02 during trading hours on Tuesday, hitting $2.12. 71,377 shares of the company were exchanged, compared to its average volume of 36,401. BioHarvest Sciences has a 52-week low of $1.82 and a 52-week high of $12.80. The company has a current ratio of 2.96, a quick ratio of 2.44 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $2.77 and a 200 day simple moving average of $3.82. The stock has a market capitalization of $41.67 million, a price-to-earnings ratio of -3.60 and a beta of 0.98.
Key BioHarvest Sciences News
Here are the key news stories impacting BioHarvest Sciences this week:
- Positive Sentiment: BioHarvest secured an exclusive manufacturing and supply agreement with an existing UAE-based fragrance customer for 20 tons of a rare botanical fragrance ingredient over 2027 and 2028. The company estimates the deal could generate approximately $20 million to $30 million in revenue and become the foundation of a profitable CDMO manufacturing business. BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
- Positive Sentiment: The agreement supports BioHarvest’s strategy of expanding into high-margin, sustainable fragrance manufacturing, with management indicating it will pursue additional opportunities in the rare fragrance market. The contract also provides greater visibility into future production demand. BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
- Positive Sentiment: Second-quarter revenue rose 3.8% year over year to approximately $8.8 million, while the company said spending was being directed toward manufacturing capacity to support future growth. BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
Institutional Inflows and Outflows
Analyst Ratings Changes
Separately, Weiss Ratings raised shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.
Get Our Latest Stock Analysis on BHST
About BioHarvest Sciences
BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.
The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.
See Also
- Five stocks we like better than BioHarvest Sciences
- Tesla’s Energy Business Just Got a SpaceX Demand Signal
- Oklo’s Revenue Transition Gives Bulls a New Reason to Watch
- Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
- AMD’s Helios Launch Could Create Winners Beyond AMD Stock
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
